Scribe Therapeutics Inc. (SCTX)Healthcare | Biotechnology | Alameda, United States | NasdaqGM
20.08 USD
-0.64
(-3.089%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 20.08 |
Hot Take ↕ | Oct. 10, 2026, 10:53 a.m. EDT
The immediate outlook is severely clouded by a violent technical breakdown. Despite a recent rally from the lows, the stock has collapsed over the last week, tumbling from $28 to $16. This precipitous drop has shattered key moving averages, leaving the price trading significantly below both the 50-day and 200-day averages, which now act as heavy resistance. The lack of any statistical forecasting model due to insufficient data further suggests the market is in a state of high uncertainty, making any short-term entry a gamble against a downward trend. Looking further ahead, the fundamental picture is dire for a traditional investor. The company is burning cash aggressively with negative operating cash flow and shrinking revenues by over 60%. The balance sheet is precarious, with debt nearly matching cash reserves and a current ratio well below 1.0, indicating an inability to cover short-term obligations without raising capital. While the massive IPO and high analyst price targets hint at a speculative 'lottery ticket' thesis where the market expects a future cure to justify the current valuation, the current reality is a distressed biotech with deteriorating fundamentals and no dividend support. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 13.583 |
| Market Cap | 380,148,128 |
| Forward P/E | -5.55 |
| Profit Margins | -97.00% |
| Website | https://www.scribetx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.09225094 |
| Address1 | 1,150 Marina Village Pkwy |
| All Time High | 39.6 |
| All Time Low | 13.5 |
| Ask | 18.76 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 459,790 |
| Average Daily Volume3 Month | 357,270 |
| Average Volume | 357,270 |
| Average Volume10Days | 459,790 |
| Bid | 14.57 |
| Bid Size | 4 |
| Book Value | -66.33 |
| City | Alameda |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 20.08 |
| Current Ratio | 0.573 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 21.0 |
| Day Low | 19.72 |
| Display Name | Scribe Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | -27,820,000 |
| Ebitda Margins | -0.83539003 |
| Enterprise To Ebitda | -18.027 |
| Enterprise To Revenue | 15.06 |
| Enterprise Value | 501,522,400 |
| Eps Current Year | -5.59 |
| Eps Forward | -3.61667 |
| Eps Trailing Twelve Months | -3.84 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 25.747 |
| Fifty Day Average Change | -5.667 |
| Fifty Day Average Change Percent | -0.22010331 |
| Fifty Two Week Change Percent | 9.225094 |
| Fifty Two Week High | 39.6 |
| Fifty Two Week High Change | -19.519999 |
| Fifty Two Week High Change Percent | -0.49292928 |
| Fifty Two Week Low | 13.5 |
| Fifty Two Week Low Change | 6.58 |
| Fifty Two Week Low Change Percent | 0.48740742 |
| Fifty Two Week Range | 13.5 - 39.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,785,159,000,000 |
| Float Shares | 6,889,049 |
| Forward Eps | -3.61667 |
| Forward P E | -5.5520687 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 82 |
| Fullday Change | -0.6399994 |
| Fullday Change Percent | -3.0888002 |
| Fullday Price | 20.08 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.53285 |
| Gross Profits | -17,745,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18037 |
| Held Percent Institutions | 0.54523 |
| Implied Shares Outstanding | 18,931,680 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-07-24 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California. |
| Long Name | Scribe Therapeutics Inc. |
| Market | us_market |
| Market Cap | 380,148,128 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_642070737 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -32,304,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 502,257,470 |
| Number Of Analyst Opinions | 4 |
| Open | 20.86 |
| Operating Cashflow | -37,853,000 |
| Operating Margins | -4.89833 |
| Phone | 510 626 8587 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 20.08 |
| Post Market Time | 1,792,182,375 |
| Previous Close | 20.72 |
| Price Eps Current Year | -3.5921288 |
| Price Hint | 2 |
| Price To Book | -0.30272877 |
| Price To Sales Trailing12 Months | 11.4151745 |
| Profit Margins | -0.97003 |
| Quick Ratio | 0.562 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.6399994 |
| Regular Market Change Percent | -3.0888002 |
| Regular Market Day High | 21.0 |
| Regular Market Day Low | 19.72 |
| Regular Market Day Range | 19.72 - 21.0 |
| Regular Market Open | 20.86 |
| Regular Market Previous Close | 20.72 |
| Regular Market Price | 20.08 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 201,393 |
| Revenue Growth | -0.608 |
| Revenue Per Share | 13.583 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 18,931,680 |
| Shares Percent Shares Out | 0.1303 |
| Shares Short | 2,466,931 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 778,191 |
| Short Name | Scribe Therapeutics Inc. |
| Short Ratio | 5.68 |
| Source Interval | 15 |
| State | CA |
| Symbol | SCTX |
| Target High Price | 60.0 |
| Target Low Price | 50.0 |
| Target Mean Price | 57.0 |
| Target Median Price | 59.0 |
| Total Cash | 43,009,000 |
| Total Cash Per Share | 2.272 |
| Total Debt | 43,270,000 |
| Total Revenue | 33,302,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.84 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 24.988276 |
| Two Hundred Day Average Change | -4.9082756 |
| Two Hundred Day Average Change Percent | -0.19642314 |
| Type Disp | Equity |
| Volume | 201,393 |
| Website | https://www.scribetx.com |
| Zip | 94,501 |